- English (USA)
- English (UK)
- English (India)
- English (Australia)
- English (South Africa)
- English (Philippines)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Medivir AB ser. B (MEDIVIR)
Medivir AB ser. B stock price live, this page displays ST MEDIVIR stock exchange data. View the MEDIVIR premarket stock price ahead of the market session or assess the after hours quote. Monitor the latest movements within the Medivir AB ser. B real time stock price chart below.
What Is the Medivir AB ser. B Stock Price Today?
The Medivir AB ser. B stock price today is 2.04.
What Is the Stock Symbol for Medivir AB ser. B?
The stock symbol for Medivir AB ser. B is "MEDIVIR."
What Stock Exchange Does Medivir AB ser. B Trade On?
Medivir AB ser. B is listed and trades on the Stockholm stock exchange.
Is Medivir AB ser. B a Good Stock to Buy?
Determining whether Medivir AB ser. B—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the MEDIVIR quote. (ISIN: SE0020181014)
What Is the Medivir AB ser. B Stock Price Today?
The Medivir AB ser. B stock price today is 2.04.
What Is the Stock Symbol for Medivir AB ser. B?
The stock symbol for Medivir AB ser. B is "MEDIVIR."
What Stock Exchange Does Medivir AB ser. B Trade On?
Medivir AB ser. B is listed and trades on the Stockholm stock exchange.
Is Medivir AB ser. B a Good Stock to Buy?
Determining whether Medivir AB ser. B—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the MEDIVIR quote. (ISIN: SE0020181014)
2.04
+0.04(+2.06%)
Closed·
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
1.93
2.10
52 wk Range
0.34
2.89
MEDIVIR is not included in our AI-picked strategies. See which stocks are.
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
1.932.10
52 wk Range
0.342.89
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
MEDIVIR Scorecard
Company’s Health
Assesses a company's financial position by analyzing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Strong Buy
Price Target
4.98
Upside
+144.07%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
Significant return over the last week
- Medivir Q1 revenue rises, EBITDA loss narrows
- Investing.com
- Medivir receives Investment Bank Analyst Rating Update
- Investing.com
Pro
- Medivir Q1 revenue rises, EBITDA loss narrows
- Investing.com
- Medivir receives Investment Bank Analyst Rating Update
- Investing.com
Pro
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Buy
Technical Indicators
Strong Buy
Moving Averages
Strong Buy
Analyst Ratings
1 Buy
0 Hold
0 Sell
Ratings:
1 analysts
Overall Consensus
Buy
Analysts 12-Month Price Target:
Average 4.98
(+144.07% Upside)
Earnings
Latest Release
May 05, 2026
EPS / Forecast
-- / -0.09
Revenue / Forecast
1.22M / --
Compare MEDIVIR to Peers and Sector
Metrics to compare | MEDIVIR | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipMEDIVIRPeersSector | |
|---|---|---|---|---|
P/E Ratio | −11.9x | −3.5x | −0.5x | |
PEG Ratio | −0.20 | −0.12 | 0.00 | |
Price/Book | 5.6x | 3.8x | 2.6x | |
Price / LTM Sales | 119.3x | 17.1x | 3.1x | |
Upside (Analyst Target) | 96.1% | 129.2% | 54.0% | |
Fair Value Upside | Unlock | 0.0% | 6.5% | Unlock |
Medivir AB (publ), a pharmaceutical company, focuses on the development and commercialization of medical treatments in areas of high unmet medical need in Sweden, the Nordic region, the rest of Europe, and internationally. The company offers Xerclear (Zoviduo), a combination of a polymerase inhibitor and hydrocortisone for the treatment of labial herpes; and Olysio (simeprevir), a protease inhibitor for the treatment of hepatitis C. It also develops remetinostat, a histone deacetylase (HDAC) inhibitor that is in a Phase II trial for the treatment of mycosis fungoides cutaneous T-cell lymphoma (MF-CTCL), basal cell carcinoma (BCC), and squamous cell carcinoma (SCC); MIV-711, a potent and selective cathepsin K inhibitor that is in a Phase II trial for the treatment of osteoarthritis, as well as in Phase I trials for the treatment of Osteogenesis Imperfecta (brittle bone disease) and Legg-Calvé-Perthes disease (LCPD); and fostroxacitabine bralpamide (fostrox), a liver-targeted inhibitor of DNA replication, which is in Phase I and II trials for the treatment of hepatocellular carcinoma. In addition, the company is developing birinapant, a SMAC-mimetic for the treatment of solid tumors; VBX-1000 (MIC-701), a selective cathepsin K inhibitor for the treatment of canine periodontitis; USP-7, a preclinical research program for the treatment of cancer; and MET-X (MBLI), a preclinical project for the treatment of infection. Medivir AB (publ) was incorporated in 1987 and is based in Huddinge, Sweden.
Ownership
Ownership Overview
Top Holders
People Also Watch
FAQ
What Is the Medivir B (MEDIVIR) Stock Price Today?
The Medivir B stock price today is 2.04 SEK.
What Stock Exchange Does Medivir B Trade On?
Medivir B is listed and trades on the Stockholm Stock Exchange.
What Is the Stock Symbol for Medivir B?
The stock symbol for Medivir B is "MEDIVIR."
What Is the Medivir B Market Cap?
As of today, Medivir B market cap is 1.07B SEK.
What Is Medivir B's Earnings Per Share (TTM)?
The Medivir B EPS (TTM) is -0.39.
When Is the Next Medivir B Earnings Date?
Medivir B will release its next earnings report on Aug 20, 2026.
From a Technical Analysis Perspective, Is MEDIVIR a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Buy.
How Many Times Has Medivir B Stock Split?
Medivir B has split 4 times.
How Many Employees Does Medivir B Have?
Medivir B has 10 employees.
What is the current trading status of Medivir B (MEDIVIR)?
As of May 21, 2026, Medivir B (MEDIVIR) is trading at a price of 2.04 SEK, with a previous close of 1.99 SEK. The stock has fluctuated within a day range of 1.93 SEK to 2.10 SEK, while its 52-week range spans from 0.34 SEK to 2.89 SEK.
What Is Medivir B (MEDIVIR) Price Target According to Analysts?
The average 12-month price target for Medivir B is 4.98 SEK, with a high estimate of 6.937 SEK and a low estimate of 4 SEK. 1 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Buy. The stock has an +144.07% Upside potential.
Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.